Thrombolex Announces Enrollment of 100th Patient in RAPID-PE Clinical Study
Thrombolex, Inc. has announced the enrollment of the 100th patient in its RAPID-PE clinical study, marking a significant milestone that reflects growing clinical confidence in the BASHIR® Endovascular System for treating intermediate-risk pulmonary embolism.
Thrombolex, Inc., today announced the enrollment of the 100th patient in the RAPID-PE clinical study. This significant milestone underscores the growing clinical confidence in the BASHIR® Endovascular System and the urgency of generating robust evidence for the treatment of intermediate-risk pulmonary embolism (PE). [PR.com]